This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Concert Pharmaceuticals Gestion
Gestion contrôle des critères 2/4
Informations clés
Roger Tung
Directeur général
US$3.5m
Rémunération totale
| Pourcentage du salaire du PDG | 17.0% |
| Durée du mandat du directeur général | 16.9yrs |
| Propriété du PDG | 1.4% |
| Durée moyenne d'occupation des postes de direction | 4.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 16.3yrs |
Mises à jour récentes de la gestion
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$127m |
| Jun 30 2022 | n/a | n/a | -US$125m |
| Mar 31 2022 | n/a | n/a | -US$95m |
| Dec 31 2021 | US$4m | US$599k | -US$80m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$59m |
| Mar 31 2021 | n/a | n/a | -US$77m |
| Dec 31 2020 | US$3m | US$582k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$73m |
| Jun 30 2020 | n/a | n/a | -US$71m |
| Mar 31 2020 | n/a | n/a | -US$77m |
| Dec 31 2019 | US$3m | US$562k | -US$78m |
| Sep 30 2019 | n/a | n/a | -US$79m |
| Jun 30 2019 | n/a | n/a | -US$79m |
| Mar 31 2019 | n/a | n/a | -US$73m |
| Dec 31 2018 | US$5m | US$536k | -US$56m |
| Sep 30 2018 | n/a | n/a | -US$41m |
| Jun 30 2018 | n/a | n/a | US$104m |
| Mar 31 2018 | n/a | n/a | US$104m |
| Dec 31 2017 | US$3m | US$517k | US$95m |
| Sep 30 2017 | n/a | n/a | US$89m |
| Jun 30 2017 | n/a | n/a | -US$50m |
| Mar 31 2017 | n/a | n/a | -US$50m |
| Dec 31 2016 | US$3m | US$500k | -US$51m |
Rémunération vs marché: Roger's total compensation ($USD3.53M) is above average for companies of similar size in the US market ($USD2.48M).
Rémunération et revenus: Roger's compensation has increased whilst the company is unprofitable.
PDG
Roger Tung (62 yo)
16.9yrs
Titularisation
US$3,526,782
Compensation
Dr. Roger D. Tung, Ph D., Co-founded Concert Pharmaceuticals, Inc. in April 2006 and has been its Chief Executive Officer and President since April 2006. Dr. Tung worked in venture-backed start-up and majo...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder & Independent Chairman of the Board | 16.8yrs | US$129.05k | 0.89% $ 4.6m | |
| Co-Founder | 16.9yrs | US$3.53m | 1.37% $ 7.1m | |
| Chief Financial Officer | 5.2yrs | US$1.38m | 0.20% $ 1.0m | |
| Chief Development Officer | 8.1yrs | US$1.51m | 0.13% $ 674.6k | |
| Chief Operating Officer | 15.4yrs | US$1.58m | 0.27% $ 1.4m | |
| Senior Vice President of Corporate Communications & Investor Relations | no data | pas de données | pas de données | |
| Chief Legal Officer & Corporate Secretary | 3.5yrs | pas de données | 0.062% $ 321.0k | |
| Vice President of Corporate Development | 1.2yrs | pas de données | pas de données | |
| Vice President of Human Resources | less than a year | pas de données | pas de données | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 1.2yrs | pas de données | pas de données |
4.3yrs
Durée moyenne de l'emploi
63yo
Âge moyen
Gestion expérimentée: CNCE's management team is considered experienced (4.3 years average tenure).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Co-Founder & Independent Chairman of the Board | 16.8yrs | US$129.05k | 0.89% $ 4.6m | |
| Co-Founder | 16.9yrs | US$3.53m | 1.37% $ 7.1m | |
| Independent Director | 6.9yrs | US$99.05k | 0.041% $ 214.7k | |
| Independent Director | 16.3yrs | US$94.05k | 0.021% $ 109.6k | |
| Independent Director | 16.8yrs | US$106.55k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$96.55k | 0.0082% $ 42.9k | |
| Independent Director | 8.3yrs | US$109.05k | 0.028% $ 147.5k |
16.3yrs
Durée moyenne de l'emploi
65yo
Âge moyen
Conseil d'administration expérimenté: CNCE's board of directors are seasoned and experienced ( 16.3 years average tenure).